Cited 0 times in
Atypical hemolytic uremic syndrome: Korean pediatric series.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, JM | - |
dc.contributor.author | Park, YS | - |
dc.contributor.author | Lee, JH | - |
dc.contributor.author | Park, SJ | - |
dc.contributor.author | Shin, JI | - |
dc.contributor.author | Park, YH | - |
dc.contributor.author | Yoo, KH | - |
dc.contributor.author | Cho, MH | - |
dc.contributor.author | Kim, SY | - |
dc.contributor.author | Kim, SH | - |
dc.contributor.author | Namgoong, MK | - |
dc.contributor.author | Lee, SJ | - |
dc.contributor.author | Cho, HY | - |
dc.contributor.author | Han, KH | - |
dc.contributor.author | Kang, HG | - |
dc.contributor.author | Ha, IS | - |
dc.contributor.author | Bae, JS | - |
dc.contributor.author | Kim, NK | - |
dc.contributor.author | Park, WY | - |
dc.contributor.author | Cheong, HI | - |
dc.date.accessioned | 2017-03-21T06:00:38Z | - |
dc.date.available | 2017-03-21T06:00:38Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1328-8067 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/13608 | - |
dc.description.abstract | BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare disease with a genetic predisposition. Few studies have evaluated the disease in the Asian population. We studied a Korean pediatric cohort to delineate the clinical characteristics and genotypes.
METHODS: A multicenter cohort of 51 Korean children with aHUS was screened for mutations using targeted exome sequencing covering 46 complement related genes. Anti-complement-factor-H autoantibody (anti-CFH) titers were measured. Multiplex ligation-dependent probe amplification assay was performed to detect deletions in the complement factor-H related protein genes (CFHR) in the patients as well as in 100 healthy Korean controls. We grouped the patients according to etiology and compared the clinical features using Mann-Whitney U-test and chi-squared test. RESULTS: Fifteen patients (group A, 29.7%) had anti-CFH, and mutations were detected in 11 (group B, 21.6%), including one with combined mutations. The remaining 25 (group C, 49.0%) were negative for both. The prevalence of anti-CFH was higher than the worldwide level. Group A had a higher onset age than group B, although the difference was not significant. Group B had the worst renal outcome. Gene frequencies of homozygous CFHR1 deletion were 73.3%, 2.7% and 1% in group A, group B + C and the control, respectively. CONCLUSIONS: The incidence of anti-CFH in the present Korean aHUS cohort was high. Clinical outcomes largely conformed to the previous reports. Although the sample size was limited, this cohort provides a reassessment of clinicogenetic features of aHUS in Korean children. | - |
dc.language.iso | en | - |
dc.subject.MESH | Atypical Hemolytic Uremic Syndrome | - |
dc.subject.MESH | Autoantibodies | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Complement Factor H | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gene Frequency | - |
dc.subject.MESH | Genetic Predisposition to Disease | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Multiplex Polymerase Chain Reaction | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Republic of Korea | - |
dc.title | Atypical hemolytic uremic syndrome: Korean pediatric series. | - |
dc.type | Article | - |
dc.identifier.pmid | 25443527 | - |
dc.contributor.affiliatedAuthor | 박, 세진 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1111/ped.12549 | - |
dc.citation.title | Pediatrics international | - |
dc.citation.volume | 57 | - |
dc.citation.number | 3 | - |
dc.citation.date | 2015 | - |
dc.citation.startPage | 431 | - |
dc.citation.endPage | 438 | - |
dc.identifier.bibliographicCitation | Pediatrics international, 57(3). : 431-438, 2015 | - |
dc.identifier.eissn | 1442-200X | - |
dc.relation.journalid | J013288067 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.